On the pulse: IPL therapy's role in treating meibomian gland dysfunction
19 August 2022
Summer 2022
Evaporative dry eye resulting from meibomian gland dysfunction has been difficult to treat, writes Kim Thomas. But intense pulsed light therapy is being increasingly deployed to tackle it. So does it really work?
Domains covered
Communication
Clinical practice
Meibomian gland dysfunction (MGD), also known as posterior lid margin disease, is caused by posterior blepharitis. Bacterial lipases break down meibomian lipids, causing meibomian secretions to become both chemically and physically abnormal. The result is an unstable tear film causing dry eye symptoms of irritation, redness and blurred vision. MGD is common, with a pooled prevalence of 35.8%, though men are more prone to the condition than women, and it is more prevalent in people of Arab, Asian or Hispanic origin (Hassanzadeh et al, 2021). The unpleasantness of the symptoms can affect the mental health of patients with MGD, who may experience crying spells, sleep disturbance and depressed appetite (Wei et al, 2022).
Not already a member of the College?
Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
Related further reading
The College of Optometrists presented the annual Research Excellence Awards to 2024’s winners at its prestigious annual Diploma and Awards Ceremony on 12 November, held at Central Hall in Westminster, London.
This live webinar by Dr Rakhee Shah and Mr Simon Raw provides up-to-date guidance and research for adapting an eye examination to suit the needs of a patient with dementia.
The Clinical Management Guidelines (CMGs) set out the evidence to inform your clinical practice and support professional judgement with respect to diagnosis and management.